ANALYSIS OF THE IMPORTANCE OF PHARMACOTHERAPY IN PREVENTING SERIOUS COMPLICATIONS CAUSED BY CARDIOVASCULAR DISEASES

Globally, cardiovascular disease (CVD) is the leading cause of death. Our goal was to use clinician-assessed absolute risk level to estimate the effects of CVD preventive double medication (a statin and an anti-hypertensive). For the entire population of New Zealand (NZ), a multi-state life-table model that has been proven and validated was modified. A published NZ-specific CVD risk equation was used to stratify the 60–64-year-old male population by risk in the updated model. Although a lifetime horizon was employed to measure benefits and costs, a five-year horizon was also used throughout the five-year intervention period of treatment. In all absolute risk categories, we discovered that providing double therapy was very cost-effective for this group (e.g., NZ$1580 per QALY gained in the >20% in 5 years risk stratum; 95%UI: Dominant to NZ$3990). The cost per QALY was only NZ$25,500 (NZ$28,200 and US$19,100 in 2018), even in the lowest risk stratum (≤5% risk in 5 years). Individual quality-adjusted life gains for those who accepted the screening offer and started preventive therapy varied from 0.6 to 4.9 months (or less than a month with a five-year horizon). However, at the individual level, patient considerations are crucial since some people may determine that taking daily medicine is not worth the average health advantage. According to the study's findings, over half of the participants had drug therapy issues, and 58% of them needed more medication. It has been discovered that using more than three medications increases the chance of drug therapy issues. This is an area that needs special attention and the collaboration of healthcare professionals to address because these issues are negatively impacting patients' treatment outcomes.